QCLS vs VNRX

Q/C Technologies, Inc. vs VolitionRX Limited — Valuation Comparison 2026

QCLS

In Vitro & In Vivo Diagnostic Substances
Q/C Technologies, Inc.
Quality
4.0
out of 10
Value Trap
25
LOW
Price
$4.37
Last close
Models
7/13
Active
VS

VNRX

In Vitro & In Vivo Diagnostic Substances
VolitionRX Limited
Quality
5.8
out of 10
Value Trap
18
SAFE
Price
$2.67
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType QCLS Fair ValueQCLS Upside VNRX Fair ValueVNRX Upside
Bayesian DCF Intrinsic $1.21 -72.3% $0.40 -85.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.11 -97.5% $0.14 +1.1%
PWERM Option-Based $5.79 +32.5% $6.36 +138.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for QCLS vs VNRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QCLS vs VNRX — Which Stock Is More Undervalued?

VNRX scores higher with a 5.8/10 quality rating vs QCLS's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Q/C Technologies, Inc. (QCLS) and VolitionRX Limited (VNRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QCLS currently trades at $4.37 with a QOC of 4.0/10, while VNRX trades at $2.67 with a QOC of 5.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).